A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041)



Status:Archived
Conditions:Breast Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:September 2010
End Date:November 2013

Use our guide to learn which trials are right for you!

A Two-Part Adaptive, Randomized Trial of Ridaforolimus in Combination With Dalotuzumab Compared to Exemestane or Compared to Ridaforolimus or Dalotuzumab Monotherapy in Estrogen Receptor Positive Breast Cancer Patients


This is a two-part study that will determine, if: 1) the combination of ridaforolimus and
dalotuzumab will improve progression-free survival compared to exemestane; and 2) the
combination of ridaforolimus and dalotuzumab will improve progression-free survival compared
to both ridaforolimus and dalotuzumab as single agents, in participants with breast cancer.



We found this trial at
13
sites
?
mi
from
Aurora, CO
Click here to add this to my saved trials
?
mi
from
Abington, PA
Click here to add this to my saved trials
Asheville, North Carolina 28805
?
mi
from
Asheville, NC
Click here to add this to my saved trials
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
?
mi
from
Bloomington, MN
Click here to add this to my saved trials
?
mi
from
Camden, NJ
Click here to add this to my saved trials
?
mi
from
Dallas, TX
Click here to add this to my saved trials
?
mi
from
Kansas City, MO
Click here to add this to my saved trials
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
New Britain, Connecticut 06052
?
mi
from
New Britain, CT
Click here to add this to my saved trials
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Springfield, Massachusetts 01199
?
mi
from
Springfield, MA
Click here to add this to my saved trials
Springfield, Massachusetts 01199
?
mi
from
Springfield, MA
Click here to add this to my saved trials